Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.47−0.02 (-4.78%)
Close on Nov 13, 2026Market cap $131.40MP/E –Yield –
Akebia Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Akebia Therapeutics's ebitda for the twelve months ending Mar 31, 2020 was -$267.11M. For fiscal 2022 it was -$79.13M. The highest annual figure on record is -$37.89M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$79.13M | – |
| FY2021 | Dec 31, 2021 | -$262.58M | – |
| FY2020 | Dec 31, 2020 | -$375.75M | – |
| FY2019 | Dec 31, 2019 | -$284.04M | – |
| FY2018 | Dec 31, 2018 | -$177.26M | – |
| FY2017 | Dec 31, 2017 | -$76.06M | – |
| FY2016 | Dec 31, 2016 | -$136.16M | – |
| FY2015 | Dec 31, 2015 | -$61.42M | – |
| FY2014 | Dec 31, 2014 | -$37.89M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2020 | Mar 31, 2020 | -$58.60M | – |
| Q4 FY2019 | Dec 31, 2019 | -$94.31M | – |
| Q3 FY2019 | Sep 30, 2019 | -$55.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$58.94M | – |
| Q1 FY2019 | Mar 31, 2019 | -$75.53M | – |
| Q4 FY2018 | Dec 31, 2018 | -$89.90M | -707.1% |
| Q3 FY2018 | Sep 30, 2018 | -$27.62M | – |
| Q2 FY2018 | Jun 30, 2018 | -$35.45M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.30M | – |
| Q4 FY2017 | Dec 31, 2017 | $14.81M | – |
| Q3 FY2017 | Sep 30, 2017 | -$24.01M | – |
| Q2 FY2017 | Jun 30, 2017 | -$22.02M | – |
| Q1 FY2017 | Mar 31, 2017 | -$44.84M | – |
| Q4 FY2016 | Dec 31, 2016 | -$37.92M | – |
See a number that looks wrong?